-
Product Insights
NewNet Present Value Model: Tango Therapeutics Inc’s TNG-348
Empower your strategies with our Net Present Value Model: Tango Therapeutics Inc's TNG-348 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Tango Therapeutics Inc’s TNG-908
Empower your strategies with our Net Present Value Model: Tango Therapeutics Inc's TNG-908 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNG-462 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNG-462 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNG-462 in Solid Tumor Drug Details: TNG-462 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNG-260 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNG-260 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNG-260 in Solid Tumor Drug Details: TNG-260 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNG-260 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNG-260 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNG-260 in Metastatic Pancreatic Cancer Drug Details: TNG-260 is under...